Get the Stockscreener App
231.55
0.68%
-1.28
Overview
News
Price History
Option Chain
Financials
Why ABBV Down?
Discussions
Forecast
Dividend History
Abbvie Inc stock is traded at $231.55, with a volume of 150.95K.
It is down -0.68% in the last 24 hours and up +10.23% over the past month.
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio.
See More
Previous Close:
$232.83
Open:
$231.48
24h Volume:
150.95K
Relative Volume:
0.03
Market Cap:
$408.98B
Revenue:
$58.33B
Net Income/Loss:
$3.73B
P/E Ratio:
110.19
EPS:
2.1013
Net Cash Flow:
$18.24B
1W Performance:
-5.37%
1M Performance:
+10.23%
6M Performance:
+31.64%
1Y Performance:
+19.81%
1-Day Range:
$231.03
$232.16
1-Week Range:
$227.59
$242.67
52-Week Range:
$163.81
$244.81
Abbvie Inc Stock (ABBV) Company Profile
Name
Abbvie Inc
Sector
Industry
Phone
(847) 932-7900
Address
1 NORTH WAUKEGAN ROAD, NORTH CHICAGO, IL
Compare ABBV with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ABBV
Abbvie Inc
|
231.51 | 411.31B | 58.33B | 3.73B | 18.24B | 2.1013 |
|
LLY
Lilly Eli Co
|
849.97 | 756.28B | 53.26B | 13.80B | -50.20M | 15.08 |
|
JNJ
Johnson Johnson
|
189.15 | 454.91B | 90.62B | 22.66B | 18.18B | 9.35 |
|
NVS
Novartis Ag Adr
|
132.75 | 254.66B | 53.40B | 13.68B | 16.89B | 6.8864 |
|
MRK
Merck Co Inc
|
87.78 | 218.83B | 63.43B | 16.42B | 14.72B | 6.4861 |
Abbvie Inc Stock (ABBV) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-01-25 | Downgrade | HSBC Securities | Buy → Hold |
| Sep-17-25 | Upgrade | Berenberg | Hold → Buy |
| Aug-12-25 | Resumed | Piper Sandler | Overweight |
| Aug-07-25 | Upgrade | Daiwa Securities | Neutral → Outperform |
| May-14-25 | Downgrade | Citigroup | Buy → Neutral |
| Apr-22-25 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-10-24 | Resumed | BofA Securities | Neutral |
| Dec-05-24 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Nov-22-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Nov-15-24 | Initiated | Wolfe Research | Outperform |
| Nov-04-24 | Upgrade | Argus | Hold → Buy |
| Oct-17-24 | Initiated | Bernstein | Mkt Perform |
| Jun-05-24 | Upgrade | HSBC Securities | Hold → Buy |
| May-17-24 | Initiated | Cantor Fitzgerald | Overweight |
| Jan-29-24 | Upgrade | William Blair | Mkt Perform → Outperform |
| Dec-18-23 | Downgrade | HSBC Securities | Buy → Hold |
| Dec-11-23 | Upgrade | Goldman | Neutral → Buy |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Oct-30-23 | Upgrade | Barclays | Equal Weight → Overweight |
| Oct-20-23 | Resumed | UBS | Neutral |
| Sep-29-23 | Initiated | Raymond James | Outperform |
| Jul-25-23 | Initiated | William Blair | Mkt Perform |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| Apr-05-23 | Downgrade | Argus | Buy → Hold |
| Mar-01-23 | Initiated | Guggenheim | Buy |
| Feb-22-23 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Feb-10-23 | Upgrade | SVB Securities | Underperform → Market Perform |
| Nov-18-22 | Initiated | Credit Suisse | Outperform |
| Nov-08-22 | Downgrade | Societe Generale | Buy → Hold |
| Aug-01-22 | Downgrade | Atlantic Equities | Overweight → Neutral |
| May-23-22 | Initiated | SVB Leerink | Underperform |
| May-06-22 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Apr-06-22 | Resumed | Morgan Stanley | Overweight |
| Feb-28-22 | Downgrade | UBS | Buy → Neutral |
| Feb-03-22 | Reiterated | BMO Capital Markets | Outperform |
| Feb-03-22 | Reiterated | Barclays | Equal Weight |
| Feb-03-22 | Reiterated | BofA Securities | Neutral |
| Feb-03-22 | Reiterated | Goldman | Neutral |
| Jan-13-22 | Initiated | Redburn | Buy |
| Jan-12-22 | Reiterated | BMO Capital Markets | Outperform |
| Dec-09-21 | Resumed | Wells Fargo | Overweight |
| Nov-23-21 | Upgrade | Societe Generale | Hold → Buy |
| Jul-27-21 | Resumed | Truist | Buy |
| Apr-07-21 | Resumed | RBC Capital Mkts | Outperform |
| Nov-10-20 | Resumed | Bernstein | Outperform |
| Sep-29-20 | Initiated | Berenberg | Hold |
| Jun-23-20 | Upgrade | Atlantic Equities | Neutral → Overweight |
| Jun-09-20 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Jun-02-20 | Upgrade | Argus | Hold → Buy |
| May-18-20 | Resumed | BofA/Merrill | Neutral |
| May-12-20 | Upgrade | JP Morgan | Neutral → Overweight |
| May-11-20 | Resumed | Morgan Stanley | Overweight |
| Apr-20-20 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Mar-23-20 | Downgrade | Societe Generale | Buy → Hold |
| Feb-27-20 | Initiated | Barclays | Equal Weight |
| Feb-06-20 | Initiated | Mizuho | Buy |
| Jan-07-20 | Initiated | RBC Capital Mkts | Sector Perform |
| Dec-26-19 | Reiterated | Cowen | Outperform |
| Sep-26-19 | Upgrade | Citigroup | Neutral → Buy |
| Aug-20-19 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Jun-27-19 | Upgrade | Wolfe Research | Underperform → Peer Perform |
| Jun-26-19 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| May-28-19 | Initiated | Goldman | Neutral |
| Apr-29-19 | Upgrade | BMO Capital Markets | Underperform → Market Perform |
View All
Abbvie Inc Stock (ABBV) Latest News
Dohj LLC Acquires 1,335 Shares of AbbVie Inc. $ABBV - MarketBeat
Why AbbVie and Johnson & Johnson Could Outperform Pfizer - MarketBeat
WoodTrust Financial Corp Raises Stake in AbbVie Inc. $ABBV - MarketBeat
Winthrop Advisory Group LLC Has $845,000 Position in AbbVie Inc. $ABBV - MarketBeat
Citizens National Bank Trust Department Boosts Position in AbbVie Inc. $ABBV - MarketBeat
AbbVie Inc. $ABBV is Raub Brock Capital Management LP's 10th Largest Position - MarketBeat
AbbVie Inc. $ABBV Stock Holdings Cut by Louisiana State Employees Retirement System - MarketBeat
Friedenthal Financial Acquires 1,261 Shares of AbbVie Inc. $ABBV - MarketBeat
AbbVie Inc. $ABBV Holdings Cut by Kingswood Wealth Advisors LLC - MarketBeat
Why AbbVie Stock Soared in September - Nasdaq
AbbVie (NYSE:ABBV) Stock Price Up 1.4%What's Next? - MarketBeat
Spinal Cord Injury Market Positioned for Accelerated Development Through 2034, DelveInsight Finds | Kringle Pharma, Neuroplast, Abbvie, Mitsubishi Tanabe Pharma, Lineage Cell Therapeutics, NervGen - Barchart.com
KLP Kapitalforvaltning AS Buys 19,100 Shares of AbbVie Inc. $ABBV - MarketBeat
Hardy Reed LLC Sells 1,802 Shares of AbbVie Inc. $ABBV - MarketBeat
AbbVie Inc. $ABBV Position Decreased by High Note Wealth LLC - MarketBeat
Shell Asset Management Co. Purchases 15,438 Shares of AbbVie Inc. $ABBV - MarketBeat
AbbVie 2025: Moving on - PharmaLive
SteelPeak Wealth LLC Boosts Stake in AbbVie Inc. $ABBV - MarketBeat
Presbyopia Market Analysis and Forecast Report 2025-2035 Featuring AbbVie, Eyenovia, Entod Pharma, L - PharmiWeb.com
AbbVie Announces Positive Topline Results from Phase 2 ELATE Trial Evaluating OnabotulinumtoxinA for the Treatment of Upper Limb Essential Tremor - Investing News Network
AbbVie's (ABBV) Botox Study Shows Promising Results for Essentia - GuruFocus
AbbVie's Botox Shows Improvement In Movement Disorder Study - inkl
Zacks Value Trader Highlights: Pfizer, Merck, AbbVie, Eli Lilly and Novo Nordisk - The Globe and Mail
AbbVie Stock on the Move: What Sparked the 6% Jump in the Past Week? - Yahoo Finance
AbbVie (ABBV) Achieves Positive Results in Phase 2 Trial for Essential Tremor - GuruFocus
AbbVie succeeds in mid-stage study of Botox for essential tremor - Seeking Alpha
AbbVie (ABBV) Positioned Amid Gilead's Patent Extension for Biktarvy - GuruFocus
AbbVie Says Botox Met Primary Endpoint in Phase 2 Upper Limb Essential Tremor Trial - MarketScreener
AbbVie reports positive results in essential tremor treatment trial By Investing.com - Investing.com Canada
AbbVie reports positive results in essential tremor treatment trial - Investing.com
AbbVie Says Phase 2 ELATE Trial Met Primary Endpoint For BOTOX To Treat Upper Limb Essential Tremor - Nasdaq
AbbVie announces positive phase 2 Elate trial results for onabotulinumtoxinA (Botox®) in treating upper limb essential tremor - MarketScreener
AbbVie Announces Positive Topline Results from Phase 2 ELATE Trial Evaluating OnabotulinumtoxinA (BOTOX®) for the Treatment of Upper Limb Essential Tremor - Stock Titan
AbbVie expansion win for the city - Spectrum News
Prime Capital Investment Advisors LLC Sells 30,567 Shares of AbbVie Inc. $ABBV - MarketBeat
Comprehensive Financial Consultants Institutional Inc. Grows Stake in AbbVie Inc. $ABBV - MarketBeat
Belpointe Asset Management LLC Decreases Stock Position in AbbVie Inc. $ABBV - MarketBeat
Cullinan Associates Inc. Cuts Holdings in AbbVie Inc. $ABBV - MarketBeat
Appleton Partners Inc. MA Purchases 2,010 Shares of AbbVie Inc. $ABBV - MarketBeat
Chung Wu Investment Group LLC Sells 2,360 Shares of AbbVie Inc. $ABBV - MarketBeat
Valeo Financial Advisors LLC Purchases 2,636 Shares of AbbVie Inc. $ABBV - MarketBeat
DAVENPORT & Co LLC Acquires 4,968 Shares of AbbVie Inc. $ABBV - MarketBeat
AbbVie Inc. $ABBV Holdings Raised by Grimes & Company Inc. - MarketBeat
Merit Financial Group LLC Increases Stock Position in AbbVie Inc. $ABBV - MarketBeat
Three Bridge Wealth Advisors LLC Makes New $495,000 Investment in AbbVie Inc. $ABBV - MarketBeat
Global Assets Advisory LLC Lowers Position in AbbVie Inc. $ABBV - MarketBeat
Can AbbVie Inc. stock outperform in 2025 bull marketQuarterly Performance Summary & Daily Volume Surge Signals - newser.com
Why AbbVie Inc. stock is in analyst buy zoneTrade Entry Summary & Technical Pattern Alert System - newser.com
AbbVie Inc. $ABBV Shares Acquired by Simplicity Wealth LLC - MarketBeat
Wealthcare Advisory Partners LLC Increases Holdings in AbbVie Inc. $ABBV - MarketBeat
Hill Island Financial LLC Invests $209,000 in AbbVie Inc. $ABBV - MarketBeat
Abbvie Inc Stock (ABBV) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.02%
0.80%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):